State Street Corporation (NYSE: STT) discloses 5.5% Iovance Biotherapeutics stake
Rhea-AI Filing Summary
State Street Corporation reported beneficial ownership of common stock of Iovance Biotherapeutics, Inc. This filing states that State Street and certain investment adviser subsidiaries collectively beneficially own 24,478,268 shares of Iovance common stock, representing 5.5% of the class.
The group reports 0 shares with sole voting or dispositive power, and 23,483,868 shares with shared voting power and 24,478,268 shares with shared dispositive power. Subsidiaries listed include SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 24,478,268 shares
Percent of class: 5.5%
Shared voting power: 23,483,868 shares
+3 more
6 metrics
Beneficially owned shares
24,478,268 shares
Common stock beneficially owned by State Street Corporation
Percent of class
5.5%
Percentage of Iovance common stock class held by State Street
Shared voting power
23,483,868 shares
Shares over which State Street has shared voting power
Shared dispositive power
24,478,268 shares
Shares over which State Street has shared dispositive power
Sole voting power
0 shares
Shares over which State Street has sole voting authority
Sole dispositive power
0 shares
Shares over which State Street has sole dispositive authority
Key Terms
beneficially owned, shared voting power, shared dispositive power, Schedule 13G, +1 more
5 terms
beneficially owned financial
"Item 4. | Ownership (a) | Amount beneficially owned: 24478268.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Schedule 13G regulatory
"STATE STREET CORPORATION has filed this schedule, Schedule 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
investment company financial
"shareholders of an investment company registered under the Investment Company Act of 1940"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Iovance Biotherapeutics (IOVA) is held by State Street Corporation?
State Street Corporation reports holding 5.5% of the class of Iovance Biotherapeutics common stock. This percentage is based on the company’s outstanding shares and represents a significant institutional ownership stake.
What is State Street Corporation’s dispositive power over Iovance Biotherapeutics (IOVA) shares?
The filing shows State Street has 0 shares with sole dispositive power and 24,478,268 shares with shared dispositive power. This means decisions to sell or otherwise dispose of these shares are made on a shared basis.
Which State Street subsidiaries are associated with the Iovance (IOVA) holdings?
Subsidiaries listed include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., all classified as investment advisers (IA).
Who signed the Schedule 13G filing for State Street’s Iovance (IOVA) holdings?
The Schedule 13G was signed by Elizabeth Schaefer, identified as Senior Vice President, Chief Accounting Officer of State Street Corporation, dated 08/07/2026.